HK-listed Viva Biotech unit to buy 80% in Langhua Pharma for $368m

Viva Biotech (Shanghai) Ltd, a subsidiary of  Viva Biotech Holdings, has announced plans to acquire an 80 per cent stake in the contract development manufacturing organisation (CDMO) Zhejiang Langhua Pharmaceutical for 2.56 billion yuan ($368 million). 

Viva will pay cash to acquire the stake from Langhua’s shareholders that include Ninhua Group, Nuobai Investments, and Zhining Investments, the company said in a filing to the Stock Exchange of Hong Kong on August 9.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter